ALEXANDRIA, Va., April 15 -- United States Patent no. 12,600,728, issued on April 14, was assigned to Novartis AG (Basel, Switzerland).
"Interleukin-17 inhibitors" was invented by Thomas Josef Troxler (Laufen, Switzerland), David Orain (Hesingue, France), Pascal Furet (Thann, France), Klaus Weigand (Riehen, Switzerland) and Achim Schlapbach (Basel, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds that are Interleukin-17 (IL-17) inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders med...